Table 3 Univariate analysis of in-hospital mortality and actuarial survival in critical trauma patients (n = 23)
(%) | In-hospital mortality (%) | P a | Mean survival (days) | P b | |
|---|---|---|---|---|---|
Male gender | (78.3) | 27.8 vs 20 | n.s. | 218.2 ± 36.4 vs 243.6 ± 66.5 | n.s. |
Age ≥ 60 years-old | (30.4) | 42.9 vs 18.8 | n.s. | 103.7 ± 30.7 vs 265.5 ± 37.5 | n.s. |
Charlson’s Index ≥ 1 | (17.4) | 75 vs 15.8 | 0.04 | 57 ± 34.3 vs 266.2 ± 33.8 | 0.005 |
APACHE II ≥ 19.5 | (50) | 45.5 vs 9.1 | n.s. | 152 ± 43.5 vs 310.7 ± 35.4 | 0.031 |
SAPS II ≥ 39.5 | (54.6) | 41.7 vs 10 | n.s. | 167.3 ± 42.4 vs 305 ± 38.6 | n.s. |
SOFA ≥ 7.5 | (53.9) | 42.9 vs 0 | n.s. | 0.039 | |
Injury Severity Score < 65 | (73.9) | 35.3 vs 0 | n.s. | 192.2 ± 37.6 vs 315.7 ± 45 | n.s. |
Revised Trauma Score ≥ 4.8 | (78.3) | 33.3 vs 0 | n.s. | n.s. | |
Shock index ≥ 0.75 | (54.6) | 41.7 vs 10 | n.s. | 196.5 ± 48.9 vs 273.3 ± 39.3 | n.s. |
Primary admission (yes vs no) | (21.7) | 40 vs 22.2 | n.s. | 173.6 ± 70.7 vs 237.2 ± 35.1 | n.s. |
Lactacidemia ≥ 1.25 mmol/L | (63.6) | 35.7 vs 12.5 | n.s. | 207.6 ± 42.9 vs 275.3 ± 48 | n.s. |
Arginine bioavailability < 42 % | (26.1) | 66.7 vs 11.8 | 0.021 | 87.2 ± 37.5 vs 261.4 ± 34.7 | n.s. |
Argininemia < 26 μmol/L | (17.4) | 75 vs 15.8 | 0.04 | 63.5 ± 43.9 vs 256.1 ± 33.3 | 0.031 |
Glutaminemia < 320 μmol/L | (21.7) | 60 vs 16.7 | n.s. | 70.6 ± 34.1 vs 264.8 ± 34.2 | 0.02 |
Citrullinemia ≥ 22 μmol/L | (26.1) | 50 vs 17.6 | n.s. | 151.5 ± 52.8 vs 241.2 ± 36.6 | n.s. |
Ornithinemia ≥ 72 μmol/L | (17.4) | 50 vs 21.1 | n.s. | 182.5 ± 76.7 vs 235.7 ± 35.6 | n.s. |
Arg-to-Orn ratio < 77 % | (47.8) | 45.5 vs 8.3 | n.s. | 172.1 ± 45.6 vs 268.7 ± 40.2 | n.s. |